Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

TY - JOUR

T1 - Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

AU - Davies, Melanie J

AU - D'Alessio, David A

AU - Fradkin, Judith

AU - Kernan, Walter N

AU - Mathieu, Chantal

AU - Mingrone, Geltrude

AU - Rossing, Peter

AU - Tsapas, Apostolos

AU - Wexler, Deborah J

AU - Buse, John B

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.

AB - The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.

KW - Cardiovascular Diseases/drug therapy

KW - Consensus

KW - Diabetes Mellitus, Type 2/drug therapy

KW - Europe

KW - Glucagon-Like Peptide-1 Receptor/agonists

KW - Heart Failure/drug therapy

KW - Humans

KW - Hyperglycemia/drug therapy

KW - Hypoglycemic Agents/therapeutic use

KW - Insulin/therapeutic use

KW - Liraglutide/therapeutic use

KW - Renal Insufficiency, Chronic/drug therapy

KW - Sodium-Glucose Transporter 2 Inhibitors/therapeutic use

KW - United States

U2 - 10.1007/s00125-018-4729-5

DO - 10.1007/s00125-018-4729-5

M3 - Journal article

C2 - 30288571

SN - 0012-186X

VL - 61

SP - 2461

EP - 2498

JO - Diabetologia

JF - Diabetologia

IS - 12

ER -